INVESTIGATIONAL STEAP1-TARGETED T-CELL ENGAGER (TCE) TECHNOLOGY IS

AT THE CENTER OF CHANGE IN mAPMR PROSTATE CANCER*

Also known as mCRPC

Discover the power of immunotherapy in prostate cancer

 

*Terminology introduced by the Prostate Cancer Working Group 4.
mAPMR, metastatic androgen pathway modulation-resistant; mCRPC, metastatic castration-resistant prostate cancer; STEAP1, six-transmembrane epithelial antigen of prostate 1.

AT THE CENTER OF CHANGE

THE POTENTIAL OF TCEs IN mAPMR PROSTATE CANCER

TCE technology is an established immunotherapy approach that works differently from immune checkpoint inhibitors.3

How do TCEs work?

T cell, TCE and prostate cancer cell.
How do TCEs work?

T-cell engager therapies are designed to activate T cells to target and destroy specific cells, a process that can also result in the release of cytokines. This cytokine release can lead to cytokine release syndrome (CRS), a known effect associated with T-cell engager therapies. CRS is characterized by fever and can range in severity; in more serious cases, it may lead to organ dysfunction. Clinical approaches are available for the recognition and management of CRS based on its grade.

Over the past decade, Amgen has pioneered TCE technology in tough-to-treat cancers, including acute lymphoblastic leukemia and small cell lung cancer7-10

CD3, cluster of differentiation 3; CRS, cytokine release syndrome.

INVESTIGATING STEAP1: A POTENTIAL
THERAPEUTIC TARGET

WHY ARE RESEARCHERS INTERESTED IN STEAP1 IN mAPMR PROSTATE CANCER?

STEAP1 is a cell-surface protein expressed on prostate cancer cells that is being explored as a potential target for T-cell engagement.

STEAP1 is overexpressed in ~95% of prostate tumors1
  • STEAP1 is also found in bone and lymph node metastases1
  • Expression of STEAP1 remains high across stages of prostate cancer, suggesting a viable target for a broad range of patients11
STEAP1 expression is low or absent in healthy tissue1
  • Despite its broad prevalence in prostate tumors, expression of STEAP1 is low or absent in healthy tissue, supporting its investigation as a potential therapeutic target1
Interactive visualization comparing tissue with overexpressed STEAP1 versus healthy tissue. Interactive visualization comparing tissue with overexpressed STEAP1 versus healthy tissue.
STEAP1 is overexpressed in ~95% of prostate tumors1
  • STEAP1 is also found in bone and lymph node metastases1
  • Expression of STEAP1 remains high across stages of prostate cancer, suggesting a viable target for a broad range of patients11
steap1 cell expression cell

Slide to reveal

STEAP1 expression is low or absent in healthy tissue1
  • Despite its broad prevalence in prostate tumors, expression of STEAP1 is low or absent in healthy tissue, supporting its investigation as a potential therapeutic target1

Slide to reveal

Investigational STEAP1-targeted TCE technology has the potential
to bring the power of immunotherapy to mAPMR prostate cancer4 

mAPMR PROSTATE CANCER REMAINS A DEVASTATING DISEASE

DESPITE ADVANCES IN TREATMENT, SIGNIFICANT UNMET NEEDS REMAIN FOR PATIENTS2

~14-15

MONTHS MEDIAN
OVERALL SURVIVAL

FOR PATIENTS WITH POST-TAXANE
mAPMR PROSTATE CANCER12-14

~58%

OF PATIENTS

DON'T RECEIVE SECOND-LINE
OR LATER THERAPY15

THE CLINICAL BENEFIT OF IMMUNE CHECKPOINT INHIBITORS IS LIMITED IN mAPMR PROSTATE CANCER

Unlike many other tumor types, immune checkpoint inhibitors have shown limited efficacy in prostate cancer. 
This is largely due to its immunologically "cold" tumor biology, characterized by:17,18
Graphic of DNA stand and downward arrow
LOW MUTATIONAL BURDEN
Graphic of cell surrounded by T-cells.
LIMITED T-CELL
INFILTRATION
Graphic of shield surroundingT cell.
AN IMMUNOSUPPRESSIVE MICROENVIRONMENT

Patients with mAPMR prostate cancer face a challenging
diagnosis—underscoring the need to continue advancing care

YOU'VE EXPANDED YOUR KNOWLEDGE ABOUT INVESTIGATIONAL STEAP1-TARGETING TCE TECHNOLOGY FOR mAPMR PROSTATE CANCER

~85% ~90% ~95%
Less than half More than half Nearly all
A high mutational burden Extensive T-cell
infiltration An immunosuppressive microenvironment

References: 1. Decato BE, Yang Z, Vengco I, et al. American Association for Cancer Research (AACR) annual meeting 2025; April 2025; Chicago, IL. 2. Chowdhury S, Bjartell A, Lumen N, et al. Target Oncol. 2020;15:301-315. 3. Albayrak G, Wan PK-T, Fisher K, et al. Br J Cancer. 2025;133:1241-1249. 4. Kelly WK, Appleman L, Lin C-C, et al. European Society of Medical Oncology Congress; September 2024; Barcelona, Spain. 5. Baeuerle PA, Sauer K, Grieshaber-Bouyer R, et al. J Exp Med. 2026;223(2):e20251652. 6. Spinazzola A, Iannantuono GM, Gulley JL, et al. Front Immunol. 2025;16:1665838. 7. Amgen FDA approval. 8. Amgen FDA approval SCLC. 9. Rudin CM, Brambilla E, Faivre-Finn C, et al. Nat Rev Dis Primers. 2021;7:3. 10. American Cancer Society. https://www.cancer.org/cancer/types/acute-lymphocytic-leukemia/treating.html. Accessed August 18, 2026. 11. Barroca-Ferreira J, Pais JP, Santos MM, et al. Curr Cancer Drug Targets. 2018;18:222-230. 12. de Bono JS, Oudard S, Ozguroglu M, et al. Lancet. 2010;376:1147-1154. 13. de Wit R, de Bono J, Sternberg CN, et al. N Engl J Med. 2019;381:2506-18. 14. Sartor O, de Bono J, Chi KN, et al. N Engl J Med. 2021;385:1091-103. 15. Freedland SJ, Davis M, Epstein AJ, et al. Prostate Cancer Prostatic Dis. 2023; 27:327–333. 16. Hofman MS, Emmett L, Sandhu S, et al. Lancet Oncol 2024;25:99-107. 17. Qi Z, Xu Z, Zhang L, et al. Nat Commun. 2022;13:182. 18. Wang I, Song L, Wang BY, et al. Am J Clin Exp Urol 2022;10:210-233.